What do systematic reviews say?

Summary of findings table ‐ Rifaximin plus non‐absorbable disaccharides vs non‐absorbable disaccharide

Summary of findings table ‐ Rifaximin plus non‐absorbable… probably leads to lower mortality ‐ total number compared with non‐absorbable disaccharides alone (moderate certainty).

• Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis 2023 · Cochrane Headline outcomes only
  RR 0.69 [0.55, 0.86]
  14 studies · 1946 participants
  Moderate

Summary of findings table ‐ Rifaximin plus non‐absorbable disaccharides vs non‐absorbable disaccharide

It is very uncertain whether summary of findings table ‐ Rifaximin plus non‐absorbable… changes serious adverse events ‐ total number of participants compared with non‐absorbable disaccharides alone (very low certainty).

• Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis 2023 · Cochrane Headline outcomes only
  RR 0.66 [0.45, 0.98]
  7 studies · 1076 participants
  Very low

Summary of findings table ‐ Rifaximin plus non‐absorbable disaccharides vs non‐absorbable disaccharide

Summary of findings table ‐ Rifaximin plus non‐absorbable… may leads to lower hepatic encephalopathy ‐ total number compared with non‐absorbable disaccharides alone (low certainty).

• Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis 2023 · Cochrane Headline outcomes only
  RR 0.58 [0.48, 0.71]
  17 studies · 2332 participants
  Low

Summary of findings table ‐ Rifaximin plus non‐absorbable disaccharides vs non‐absorbable disaccharide

It is very uncertain whether summary of findings table ‐ Rifaximin plus non‐absorbable… changes non‐serious adverse events ‐ total number of participants compared with non‐absorbable disaccharides alone (very low certainty).

• Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis 2023 · Cochrane Headline outcomes only
  RR 0.99 [0.86, 1.15]
  4 studies · 384 participants
  Very low

Summary of findings table ‐ Rifaximin plus non‐absorbable disaccharides vs non‐absorbable disaccharide

• Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 325 participants
  Very low

Summary of findings table ‐ Rifaximin plus non‐absorbable disaccharides vs non‐absorbable disaccharide

• Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 76 participants
  Very low